BPC-157 oral vs injection: what the rodent pharmacology shows, what it doesn't, and why vendor claims about oral bioavailability outrun the evidence.

BPC-157 is sold in both oral capsule and injectable (lyophilized, reconstitutable) forms by research-chemical vendors. The claim that the oral form is "just as effective" — or in some vendor copy, "superior for gut healing" — is partly rooted in rodent pharmacology and partly driven by market incentives. The actual evidence for the two routes is meaningfully different in character, and neither translates cleanly to human applications.

Why route matters for a peptide like BPC-157

BPC-157 is a 15-amino-acid peptide with molecular weight 1,419.5 Da. Oral peptide bioavailability is generally poor: gastric proteases (pepsin), intestinal brush-border peptidases, and the unstirred water layer all degrade peptides before they reach the portal circulation. Most peptides above ~500 Da and without specific transporter affinity are significantly degraded during GI transit.

BPC-157 has several features that could mitigate this. It is derived from gastric juice protein — suggesting some stability in the gastric environment. The Sikiric group has specifically studied whether the "stable" (arginate) form has improved oral stability versus the acetate salt. The molecular structure has proline residues at positions 3–5, and proline-rich sequences can confer resistance to certain proteases.

None of this resolves the core question: does enough intact BPC-157 cross human intestinal epithelium to reach systemic circulation at pharmacologically relevant concentrations? The rodent data suggests activity via oral administration; the human PK data does not exist.

What the oral rodent studies show

Several of the Sikiric laboratory's papers on BPC-157 have used oral (intragastric gavage) administration and shown activity in rat models of gastric ulcer, colon healing, and even some systemic effects. Key findings from this literature:

• Sikiric et al. have published multiple papers demonstrating that orally administered BPC-157 protects rat gastric mucosa against ethanol-induced damage — an effect expected for a locally active compound in the GI lumen, not requiring systemic absorption (PMID: 9503170).
• Systemic effects (tendon healing, CNS effects) observed after oral administration in rats are more surprising and have been used by vendors to argue that BPC-157 is absorbed systemically. These findings are from the same lab and have not been independently replicated at the mechanistic level.
• Gwyer et al. (2019) reviewed BPC-157 across routes and noted the consistency of GI effects across administration methods — consistent with either local luminal action or systemic absorption, without clearly distinguishing between them (PMID: 30746332).

The IP administration confound

A significant and underappreciated problem in reading the BPC-157 rodent literature is that the most common administration route in rat studies is intraperitoneal (IP) injection — a large-volume injection directly into the peritoneal cavity. IP is not a route used clinically in humans. IP administration provides very high bioavailability in rats (the peritoneum absorbs drugs efficiently) and is used in animal studies primarily for convenience.

When vendors quote rodent dose ranges and claim they translate to human SC or oral doses, they are often extrapolating from IP studies — which have significantly higher bioavailability than SC, and incomparably higher than oral. The body-weight-scaled dose from an IP rat study is not a reliable guide to the effective human SC dose, let alone the effective oral dose.

Injectable (subcutaneous) route — what the evidence supports

Subcutaneous injection bypasses first-pass degradation entirely and provides relatively predictable absorption in rodent models. Several of the Sikiric lab papers have demonstrated tendon, ligament, and muscle-healing effects via SC route in rats — making SC the route most analogous to what human researchers would use.

Even here, the translation problem applies: rat SC absorption kinetics, distribution to target tissues, and degradation rates are not human-equivalent. The pharmacokinetic profile of BPC-157 after SC injection in humans — peak plasma concentration, time-to-peak, volume of distribution, elimination half-life — has never been published.

Oral BPC-157: the "gut-healing" vendor narrative

Vendors promoting oral BPC-157 often frame it as "uniquely suited for gut healing because it acts locally in the GI tract." This is partially supported: if BPC-157 has local luminal activity (protecting the mucosa without requiring systemic absorption), then oral delivery is mechanistically appropriate for GI-targeted applications. The Sikiric lab's gastric ulcer and colon anastomosis work supports local mucosal effects.

The problem is that the same vendors then claim oral BPC-157 achieves systemic healing effects (tendon, muscle, joints) comparable to injectable forms. This requires systemic absorption — which has not been demonstrated in humans. The local-GI-activity argument does not support systemic bioavailability claims.

Reconstitution quick reference

For injectable research use, standard reconstitution uses bacteriostatic water (0.9% benzyl alcohol). A 5 mg vial in 2 mL BAC water yields 2,500 mcg/mL. Store refrigerated; stability after reconstitution is approximately 2–3 weeks per vendor data (not independently confirmed). Oral capsule preparations are pre-filled by the vendor; stability and actual peptide content are harder to verify without your own analytical testing.